haloperidol has been researched along with flunarizine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (23.81) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Brouillette, WJ; Brown, GB; Zha, C | 1 |
| Bennis, K; Ducki, S; Lesage, F; Vivier, D | 1 |
| Bertolucci, PH; De Andrade, LA; Ferraz, HB; Pereira, JS | 1 |
| Ahlemeyer, B; Krieglstein, J | 1 |
| Fadda, F; Gessa, GL; Mosca, E; Stefanini, E | 1 |
| Heikkila, RE; Manzino, L; Sonsalla, PK | 1 |
| Heikkila, RE; Manzino, L | 1 |
| Calder, L; Clikeman, J; Finnegan, KT; Karler, R; Wei, S | 1 |
| Camargos, ST; Cardoso, F; Silva Júnior, GA | 1 |
| Petkov, VD; Petkova, B | 1 |
| Amorim, SC; Costa, PG; Futuro-Neto, HA; Pires, JG; Ribeiro, CA; Saraiva, FP | 1 |
| Matsuo, H; Nasu, R; Ohtani, H; Sawada, Y | 1 |
| Armando, I; Belforte, JE; Buño, W; Magariños-Azcone, C; Pazo, JH | 1 |
| Cayabyab, FS; Hamming, KS; McRory, JE; Mezeyova, J; Parker, D; Santi, CM; Snutch, TP; Stea, A; Sutton, KG | 1 |
| Dall'Igna, OP; de Oliveira, RV; Fett, P; Gomes, MW; Lara, DR; Mantese, CE; Schuh, J; Souza, DO; Tort, AB | 1 |
| Bisol, LW; Borba, DL; Bressan, RA; Brunstein, MG; Daltio, CS; de Oliveira, RV; de Souza, SE; Lara, DR; Ottoni, GL; Paz, GE; Ramos, FL | 1 |
| Munhoz, RP; Teive, HA; Werneck, LC | 1 |
1 review(s) available for haloperidol and flunarizine
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pain; Potassium Channels, Tandem Pore Domain; Structure-Activity Relationship | 2016 |
1 trial(s) available for haloperidol and flunarizine
| Article | Year |
|---|---|
Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia.
Topics: Administration, Oral; Adult; Analysis of Variance; Antipsychotic Agents; Dopamine Antagonists; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Flunarizine; Haloperidol; Humans; Male; Metabolic Clearance Rate; Schizophrenia | 2008 |
19 other study(ies) available for haloperidol and flunarizine
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A highly predictive 3D-QSAR model for binding to the voltage-gated sodium channel: design of potent new ligands.
Topics: Ligands; Models, Molecular; Quantitative Structure-Activity Relationship; Voltage-Gated Sodium Channels | 2014 |
A study on the action of two calcium channel blockers (verapamil and flunarizine) upon an experimental model of tardive dyskinesia in rats.
Topics: Animals; Apomorphine; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Flunarizine; Haloperidol; Male; Rats; Rats, Wistar; Stereotyped Behavior; Verapamil | 1992 |
Testing drug effects against hypoxic damage of cultured neurons during long-term recovery.
Topics: Adenosine Triphosphate; Animals; Anticonvulsants; Brain Ischemia; Cell Count; Cell Survival; Cells, Cultured; Chick Embryo; Clonazepam; Diazepam; Dibenzocycloheptenes; Dizocilpine Maleate; Flunarizine; Haloperidol; Imipramine; Ketamine; Lidocaine; Nafronyl; Neurons; Pyrithioxin; Telencephalon | 1989 |
Different effects of the calcium antagonists nimodipine and flunarizine on dopamine metabolism in the rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Calcium Channel Blockers; Caudate Nucleus; Dopamine; Dose-Response Relationship, Drug; Flunarizine; Haloperidol; Male; Nimodipine; Rats; Rats, Inbred Strains | 1989 |
Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Basal Ganglia; Benzazepines; Corpus Striatum; Denervation; Dextroamphetamine; Ergolines; Female; Flunarizine; Functional Laterality; Haloperidol; Levodopa; Neural Pathways; Parkinson Disease; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Substantia Nigra | 1988 |
Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake.
Topics: Animals; Behavior, Animal; Biogenic Amines; Cerebral Cortex; Corpus Striatum; Dopamine; Female; Flunarizine; Haloperidol; Humans; Hydroxydopamines; In Vitro Techniques; Male; Mice; Motor Activity; Neurotransmitter Uptake Inhibitors; Oxidopamine; Piperazines; Rats; Rats, Inbred Strains; Stereotyped Behavior | 1984 |
Effects of L-type calcium channel antagonists on the serotonin-depleting actions of MDMA in rats.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain Chemistry; Calcium Channel Blockers; Cerebral Cortex; Flunarizine; Haloperidol; Hippocampus; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Nifedipine; Rats; Rats, Sprague-Dawley; Seizures; Serotonin; Stereotyped Behavior; Verapamil | 1993 |
Etiology of parkinsonism in a Brazilian movement disorders clinic.
Topics: Aged; Anti-Dyskinesia Agents; Brazil; Calcium Channel Blockers; Cinnarizine; Female; Flunarizine; Haloperidol; Histamine H1 Antagonists; Humans; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary | 1998 |
Behavioral changes as a result of dotarizine or flunarizine influence on dopaminergic neurotransmission in the striatum.
Topics: Administration, Oral; Animals; Area Under Curve; Benzhydryl Compounds; Calcium Channel Blockers; Catalepsy; Corpus Striatum; Dopamine Antagonists; Flunarizine; Haloperidol; Injections, Intraperitoneal; Male; Piperazines; Rats; Rats, Wistar; Stereotypic Movement Disorder; Synaptic Transmission | 1998 |
Evidence of sex related differences in the effects of calcium channel blockers on neuroleptic-induced catalepsy in mice.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Calcium Channel Blockers; Catalepsy; Dose-Response Relationship, Drug; Female; Flunarizine; Haloperidol; Male; Mice; Nimodipine; Sex Factors; Verapamil | 1999 |
Relationship between structure and drug-induced parkinsonism.
Topics: Antipsychotic Agents; Catalepsy; Cinnarizine; Drug Design; Flunarizine; Haloperidol; Humans; Parkinson Disease, Secondary; Structure-Activity Relationship; Vasodilator Agents | 2000 |
Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Calcium Channel Blockers; Calcium Channels, L-Type; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Flunarizine; Haloperidol; Male; Microinjections; Neostriatum; Nifedipine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Synapses; Synaptic Transmission | 2001 |
Differential inhibition of T-type calcium channels by neuroleptics.
Topics: Antipsychotic Agents; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Line; Dose-Response Relationship, Drug; Flunarizine; Haloperidol; Humans; Ion Channel Gating; Kidney; Patch-Clamp Techniques; Penfluridol; Pimozide; Piperidines; Transfection | 2002 |
Atypical antipsychotic profile of flunarizine in animal models.
Topics: Administration, Oral; Animals; Catalepsy; Dextroamphetamine; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Flunarizine; Haloperidol; Mice; Motor Activity; Receptors, N-Methyl-D-Aspartate; Time Factors | 2005 |
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizine; Haloperidol; Humans; Male; Methotrimeprazine; Movement Disorders; Outpatient Clinics, Hospital; Parkinsonian Disorders; Psychotic Disorders; Risperidone; Severity of Illness Index; Time Factors; Valproic Acid | 2010 |